Intelligent Bio Solutions posts Q3 net loss $6.34M on $457K rev; goodwill impairment $4.1M

INTELLIGENT BIO SOLUTIONS INC.

2024-Q3 EPS reported -$104.04 vs consensus -$5.41 ▼ miss (-1824.5%)

Combined revenue & govt support $574,738 (+199% YoY); product revenue $457,058 from Intelligent Fingerprinting acquisition.
Net loss $6.34M ($5.72 per share) vs $1.34M ($1.79) prior year; includes $4.1M non-cash goodwill impairment.
Filed 513(g) FDA submission for drug screening cartridge; granted UK patent for DSR-Plus Cartridge Reader (13th patent).
Completed biosensor Milestone 7: 4x improvement in time-to-result (<1 min); advancing to human saliva testing.
Cash and equivalents $2.3M as of March 31, 2023; new sales team and distribution hub established in Australia.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

INTELLIGENT BIO SOLUTIONS INC. reported fiscal third quarter ended March 31, 2023 results: revenue $457,058, net income $6.34 million, EPS $5.72 per share.

Period: fiscal third quarter ended March 31, 2023
Revenue: $457,058
Net income: $6.34 million
EPS: $5.72 per share
Result: reported results

Exact text from the filing

The Company’s combined revenue and government support income increased by 199% or $382,238 to $574,738 for the three months ending March 31, 2023, including revenue of $457,058, compared to the same period in 2022. The year-over-year revenue increase reflects the acquisition of Intelligent Fingerprinting Ltd. during the fiscal 2023 second quarter and the

View on SEC.gov

Browse all earnings releases →

INTELLIGENT BIO SOLUTIONS INC. filing history →

Source: SEC EDGAR

accession 0001493152-23-016746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.